Actively Recruiting
Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients
Led by South Valley University · Updated on 2025-02-11
50
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the nasal or respiratory mucosa and aerosolized nasal secretions are the most common theories. The bacteria is subsequently transported by the bloodstream to the peripheral nerves, where it can result in tissue damage from painless burns and ulcers as well as irreparable nerve damage that results in a loss of protective feeling.
CONDITIONS
Official Title
Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of both sexes with positive slit skin smear for m.leprae.
You will not qualify if you...
- Patients with hypersensitivity to sulfa drugs.
- Patients with hypersensitivity to clofazimine or rifampicin.
- Pregnant or lactating women.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qina University hospital, South Valley University Hospital
Qina, Egypt
Actively Recruiting
Research Team
L
Lydia Atef Nassief, MSc
CONTACT
E
Eisa Mohammed Hegazy, Assist. Prof
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here